DrugPatentWatch Database Preview
Patent: 8,344,153
» See Plans and Pricing
Summary for Patent: 8,344,153
| Title: | Inhibitors of phosphatidylinositol 3-kinase |
| Abstract: | The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K.gamma.. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. |
| Inventor(s): | Cottrell; Kevin Michael (Cambridge, MA), Aronov; Alex (Newton, MA), Davies; Robert J. (Watertown, MA), Come; Jon H. (Cambridge, MA), Messersmith; David (Somerville, MA), Xu; Jinwang (Framingham, MA), Bandarage; Upul Keerthi (Lexington, MA), Cao; Jingrong (Newton, MA) |
| Assignee: | Vertex Pharmaceuticals Incorporated (Cambridge, MA) |
| Application Number: | 12/796,825 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,344,153
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biogen Idec | TYSABRI | natalizumab | VIAL; SINGLE-USE | 125104 | 001 | 2004-11-23 | Start Trial | Vertex Pharmaceuticals Incorporated (Cambridge, MA) | 2029-06-10 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 8,344,153
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2010144513 | Start Trial |
| United States of America | 2010316605 | Start Trial |
| Mexico | 2011013032 | Start Trial |
| Japan | 2012529525 | Start Trial |
| European Patent Office | 2440556 | Start Trial |
| China | 102548990 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
